218 related articles for article (PubMed ID: 31816564)
1. Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates.
Blom EF; Ten Haaf K; de Koning HJ
Lung Cancer; 2020 Jan; 139():200-206. PubMed ID: 31816564
[TBL] [Abstract][Full Text] [Related]
2. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
3. Population impact of lung cancer screening in the United States: Projections from a microsimulation model.
Criss SD; Sheehan DF; Palazzo L; Kong CY
PLoS Med; 2018 Feb; 15(2):e1002506. PubMed ID: 29415013
[TBL] [Abstract][Full Text] [Related]
4. Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial.
González Maldonado S; Motsch E; Trotter A; Kauczor HU; Heussel CP; Hermann S; Zeissig SR; Delorme S; Kaaks R
Int J Cancer; 2021 Mar; 148(5):1097-1105. PubMed ID: 32930386
[TBL] [Abstract][Full Text] [Related]
5. Prognostic selection and long-term survival analysis to assess overdiagnosis risk in lung cancer screening randomized trials.
Paci E; Puliti D; Carozzi FM; Carrozzi L; Falaschi F; Pegna AL; Mascalchi M; Picozzi G; Pistelli F; Zappa M;
J Med Screen; 2021 Mar; 28(1):39-47. PubMed ID: 32437229
[TBL] [Abstract][Full Text] [Related]
6. The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.
Li M; Zhang L; Charvat H; Callister ME; Sasieni P; Christodoulou E; Kaaks R; Johansson M; Carvalho AL; Vaccarella S; Robbins HA
Int J Cancer; 2022 Nov; 151(9):1491-1501. PubMed ID: 35809038
[TBL] [Abstract][Full Text] [Related]
7. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.
Han SS; Ten Haaf K; Hazelton WD; Munshi VN; Jeon J; Erdogan SA; Johanson C; McMahon PM; Meza R; Kong CY; Feuer EJ; de Koning HJ; Plevritis SK
Int J Cancer; 2017 Jun; 140(11):2436-2443. PubMed ID: 28073150
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer screening overdiagnosis: reports of overdiagnosis in screening for lung cancer are grossly exaggerated.
Mortani Barbosa EJ
Acad Radiol; 2015 Aug; 22(8):976-82. PubMed ID: 25772581
[TBL] [Abstract][Full Text] [Related]
9. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
10. The Screening Illustrator: separating the effects of lead-time and overdiagnosis in mammography screening.
Lousdal ML; Møller MH; Kristiansen IS; Kalager M; Wisløff T; Støvring H
Eur J Public Health; 2018 Dec; 28(6):1138-1142. PubMed ID: 29796623
[TBL] [Abstract][Full Text] [Related]
11. Extrapolation of pre-screening trends: Impact of assumptions on overdiagnosis estimates by mammographic screening.
Ripping TM; Verbeek AL; Ten Haaf K; van Ravesteyn NT; Broeders MJ
Cancer Epidemiol; 2016 Jun; 42():147-53. PubMed ID: 27153471
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer incidence trends in Norway and estimates of overdiagnosis.
van Luijt PA; Heijnsdijk EA; van Ravesteyn NT; Hofvind S; de Koning HJ
J Med Screen; 2017 Jun; 24(2):83-91. PubMed ID: 27754936
[TBL] [Abstract][Full Text] [Related]
13. Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
Durham DD; Croswell JM; Marcus PM
Lung Cancer; 2021 Mar; 153():21-24. PubMed ID: 33445120
[TBL] [Abstract][Full Text] [Related]
14. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.
Ten Haaf K; Bastani M; Cao P; Jeon J; Toumazis I; Han SS; Plevritis SK; Blom EF; Kong CY; Tammemägi MC; Feuer EJ; Meza R; de Koning HJ
J Natl Cancer Inst; 2020 May; 112(5):466-479. PubMed ID: 31566216
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
16. Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme.
Michalopoulos D; Duffy SW
J Med Screen; 2016 Dec; 23(4):192-202. PubMed ID: 26940963
[TBL] [Abstract][Full Text] [Related]
17. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
Gulati R; Feuer EJ; Etzioni R
Am J Epidemiol; 2016 Jul; 184(2):140-7. PubMed ID: 27358266
[TBL] [Abstract][Full Text] [Related]
18. Trends in Subpopulations at High Risk for Lung Cancer.
Yang P; Wang Y; Wampfler JA; Xie D; Stoddard SM; She J; Midthun DE
J Thorac Oncol; 2016 Feb; 11(2):194-202. PubMed ID: 26811226
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Specific Mortality, All-Cause Mortality, and Overdiagnosis in Lung Cancer Screening Trials: A Meta-Analysis.
Ebell MH; Bentivegna M; Hulme C
Ann Fam Med; 2020 Nov; 18(6):545-552. PubMed ID: 33168683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
